Back

Time to diagnosis among children and adolescents with cancer in Quebec, Canada: a population-based study

Mullen, C.; Barr, R. D.; Strumpf, E.; El-Zein, M.; Franco, E. L.; Malagon, T.

2026-04-13 epidemiology
10.64898/2026.04.09.26350491 medRxiv
Show abstract

BackgroundTimely cancer diagnosis in children and adolescents is critical to improving outcomes, yet substantial variation in diagnostic intervals persists across cancer types and care settings. We aimed to quantify time to diagnosis and assess variations by patient, demographic, and system-level factors. MethodsWe conducted a retrospective population-based study of children and adolescents aged 0-19 years diagnosed with one of 12 common cancers between 2010 and 2022 in Quebec, Canada. The diagnostic interval was defined as the time from first cancer-related healthcare encounter to diagnosis. We calculated medians and interquartile ranges (IQR) overall and by cancer type and used multivariable quantile regression to identify factors associated with time to diagnosis at the 25th, 50th, and 75th percentiles. ResultsAmong 2,927 individuals with cancer, diagnostic intervals varied by cancer type and age. Median intervals were longest for carcinomas (100 days; IQR 33-192) and shortest for leukemias (8 days; IQR 3-44). Compared with children living in Montreal, living in regional areas and other large urban centres was associated with longer 50th and 75th percentiles of time to diagnosis for hepatic and central nervous system (CNS) tumours. Diagnostic intervals were shorter in the post-pandemic period (2020-2022) across several cancer sites, with CNS tumours showing reductions across all quantiles. InterpretationDiagnostic timeliness differed by cancer type, age, and rurality, but not by sex, material, or social deprivation. The shorter diagnostic intervals observed in the post-pandemic period suggest that pandemic-related changes in care pathways may have expedited diagnosis for some cancers.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 18%
10.2%
2
Clinical Infectious Diseases
231 papers in training set
Top 0.6%
6.9%
3
International Journal of Cancer
42 papers in training set
Top 0.1%
6.9%
4
JAMA Network Open
127 papers in training set
Top 0.7%
4.2%
5
BMC Public Health
147 papers in training set
Top 1%
4.2%
6
American Journal of Epidemiology
57 papers in training set
Top 0.3%
3.6%
7
Scientific Reports
3102 papers in training set
Top 35%
3.6%
8
BMJ Open
554 papers in training set
Top 7%
2.8%
9
Cancer Medicine
24 papers in training set
Top 0.5%
2.6%
10
Annals of Internal Medicine
27 papers in training set
Top 0.3%
2.1%
11
Neuro-Oncology
30 papers in training set
Top 0.3%
2.1%
12
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.2%
1.9%
50% of probability mass above
13
BMC Infectious Diseases
118 papers in training set
Top 2%
1.8%
14
Eurosurveillance
80 papers in training set
Top 0.7%
1.7%
15
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.3%
1.7%
16
The Lancet Regional Health - Americas
22 papers in training set
Top 0.1%
1.7%
17
Annals of Oncology
13 papers in training set
Top 0.5%
1.7%
18
Open Forum Infectious Diseases
134 papers in training set
Top 1%
1.7%
19
JNCI Cancer Spectrum
10 papers in training set
Top 0.3%
1.5%
20
Canadian Medical Association Journal
15 papers in training set
Top 0.1%
1.3%
21
Nature Communications
4913 papers in training set
Top 56%
1.2%
22
Cancers
200 papers in training set
Top 4%
1.2%
23
International Journal of Epidemiology
74 papers in training set
Top 2%
1.2%
24
EClinicalMedicine
21 papers in training set
Top 0.5%
1.1%
25
British Journal of Cancer
42 papers in training set
Top 1%
1.1%
26
The Lancet Digital Health
25 papers in training set
Top 0.7%
1.0%
27
CMAJ Open
12 papers in training set
Top 0.2%
0.9%
28
Influenza and Other Respiratory Viruses
44 papers in training set
Top 0.3%
0.9%
29
BMC Medicine
163 papers in training set
Top 6%
0.9%
30
Pharmacoepidemiology and Drug Safety
13 papers in training set
Top 0.4%
0.8%